Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) EBITDA (2018 - 2025)

BioNexus Gene Lab's EBITDA history spans 8 years, with the latest figure at -$1.0 million for Q4 2025.

  • Quarterly results put EBITDA at -$1.0 million for Q4 2025, up 1.98% from a year ago — trailing twelve months through Dec 2025 was -$2.6 million (down 72.78% YoY), and the annual figure for FY2025 was -$2.6 million, down 72.78%.
  • EBITDA for Q4 2025 was -$1.0 million at BioNexus Gene Lab, down from -$705775.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $431764.0 in Q4 2023 to a low of -$2.6 million in Q3 2023.
  • The 5-year median for EBITDA is -$273837.5 (2024), against an average of -$353541.0.
  • The sharpest move saw EBITDA skyrocketed 731.15% in 2021, then tumbled 2294.97% in 2022.
  • Year by year, EBITDA stood at $128173.0 in 2021, then soared by 88.31% to $241359.0 in 2022, then soared by 78.89% to $431764.0 in 2023, then tumbled by 346.75% to -$1.1 million in 2024, then grew by 1.98% to -$1.0 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$1.0 million, -$705775.0, and -$249094.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.